Carbon Nanoparticles Inhibit Α-Glucosidase Activity and Induce a Hypoglycemic Effect in Diabetic Mice.
New, improved therapies to reduce blood glucose are required for treating diabetes mellitus (DM). Here, we investigated the use of a new nanomaterial candidate for DM treatment, carbon nanoparticles (CNPs). CNPs were prepared by carbonization using a polysaccharide from Arctium lappa L. root as the carbon source. The chemical structure and morphology of the CNPs were characterized using Fourier-transform infrared spectroscopy, X-ray photoelectron spectroscopy, elemental analysis, and transmission electron microscopy. CNPs were spherical, 10-20 nm in size, consisting of C, H, O, and N, and featuring various functional groups, including C=O, C=C, C-O, and C-N. In vitro, the as-prepared CNPs could inhibit α-glucosidase with an IC50 value of 0.5677 mg/mL, which is close to that of the reference drug acarbose. Moreover, in vivo hypoglycemic assays revealed that the CNPs significantly reduced fasting blood-glucose levels in mice with diabetes induced by high-fat diet and streptozocin, lowering blood glucose after intragastric administration for 42 days. To the best of our knowledge, this is the first report of CNPs exhibiting α-glucosidase inhibition and a hypoglycemic effect in diabetic mice. These findings suggest the therapeutic potential of CNPs for diabetes.
['Shao|Taili|T|', 'Yuan|Pingchuan|P|', 'Zhu|Lei|L|', 'Xu|Honggang|H|', 'Li|Xichen|X|', 'He|Shuguang|S|', 'Li|Ping|P|', 'Wang|Guodong|G|', 'Chen|Kaoshan|K|']
D000818:Animals D001786:Blood Glucose D050260:Carbohydrate Metabolism D002244:Carbon D003921:Diabetes Mellitus, Experimental D004195:Disease Models, Animal D065089:Glycoside Hydrolase Inhibitors D006801:Humans D007003:Hypoglycemia D051379:Mice D016688:Mice, Inbred NOD D053758:Nanoparticles D017550:Spectroscopy, Fourier Transform Infrared D000520:alpha-Glucosidases
carbon nanoparticles diabetes mellitus polysaccharide Arctium lappa L. root hypoglycemia